VERTEX PHARMACEUTICALS INC / MA — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$12.00B
Cost of Revenue
$1.65B
R&D
$3.91B
SG&A
$1.75B
D&A
$210M
Operating Income
$4.17B
EBITDA
$4.38B
Interest Expense
$13M
Interest Income
—
Other Income/Expense
$483M
Pretax Income
$4.64B
Tax Provision
$690M
Net Income
$3.95B
Operating Margin
34.8%
Net Margin
32.9%
Effective Tax Rate
14.9%
Deferred Tax Assets
$3.40B
Deferred Tax Liabilities
$111M
DTA Valuation Allowance
$326M
Tax Credit Carryforwards
$356M
NOL Carryforwards
—
ETR (Continuing Operations)
14.9%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
21.3%
Operating Lease Cost
$195M
Revenue YoY Variation
8.9%
Income YoY Variation
1891.9%